

Biosign Comments on Share Trading

TORONTO, ONTARIO, Tuesday, August 24, 2010 – Biosign Technologies Inc. (CNSX: BIO) (“Biosign” or the “Company”) announced today, at the request of Market Surveillance, on behalf of the Canadian National Stock Exchange, that the company is not aware of any adverse material events to report that would account for the recent trading activity in its stock.

Contact

Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: ceo@biosign.com

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT[®] medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

The CNSX has neither approved nor disapproved the contents of this press release.